Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VERUthis companyVeru Inc.	$2.19	-2.45×	3.04×	0×	-1.21×	-69.3%	0.0%	0.0%	0.0%	-124.0%	-108.5%	-54.0%	0.17×	0.36×	0×	2.43×	0.0%	1	-11.74	2	C+
ANVSAnnovis Bio, Inc.	$0.90	-2.47×	4.22×	0×	-1.79×	-22.9%	0.0%	0.0%	0.0%	-171.2%	-170.2%	-36.0%	0×	0.68×	0×	5.8×	0.0%	1	-18.04	2	C+
CELUCelularity Inc.	$0.73	-0.31×	-0.75×	1.07×	-0.81×	-1859.9%	24.4%	-230.9%	-345.4%	241.0%	-151.1%	-46.6%	-1.07×	-0.45×	-9.08×	0.15×	20.8%	3	-16.24	2	C
DYAIDyadic International, Inc.	$0.38	-4.09×	24.88×	24.89×	-4.53×	-156.5%	-88.3%	-579.9%	-597.6%	-597.6%	-113.6%	-18.6%	4.11×	-0.06×	-15.67×	2.68×	0.0%	3	-22.52	2	C
MAIAMAIA Biotechnology, Inc.	$1.09	-2.19×	20.68×	0×	384.39×	24403.2%	0.0%	0.0%	0.0%	-942.7%	-627.4%	-38.4%	0×	386.59×	0×	1.66×	0.0%	2	-2.92	1	C-
RNXTRenovoRx, Inc.	$1.30	-2.63×	5.47×	26.43×	-2.05×	-30.1%	70.9%	-1114.0%	-994.5%	-206.0%	-200.5%	-37.0%	0.04×	0.61×	0×	4.02×	0.0%	3	2.98	2	C+
Peer median	—	-2.47×	5.47×	1.07×	-1.79×	-30.1%	0.0%	-230.9%	-345.4%	-206.0%	-170.2%	-37.0%	0×	0.61×	0×	2.68×	0.0%	3	-16.24	2	—